What is NewLimit?
Founded in 2022, NewLimit is at the forefront of developing medicines that reprogram aged cells to extend patient health spans. This emerging field, gaining traction in the biotech sector, aims to not just prolong life but to improve its quality by addressing cellular aging. The company's mission aligns with a broader trend towards preemptive and regenerative medicine, positioning it as a key player in the future of healthcare.
How much funding has NewLimit raised?
NewLimit has raised a total of $605M across 3 funding rounds:
Series A
$40M
Series B
$130M
Series C
$435M
Series A (2023): $40M with participation from Dimension Capital Management, Founders Fund, and Kleiner Perkins
Series B (2025): $130M led by Kleiner Perkins, Khosla Ventures, and The Human Capital Institute
Series C (2026): $435M supported by Kleiner Perkins, Thrive Capital, Valor Equity Partners, Founders Fund, Quiet Capital, Greenoaks, and Abstract
Key Investors in NewLimit
Kleiner Perkins
Kleiner Perkins is a Menlo Park-based venture capital firm that raises dedicated funds and invests in early and growth-stage technology and life science companies, backing founders across consumer, enterprise, healthcare, and climate/hard tech with capital and operational support from seed through IPO or acquisition.
Thrive Capital
Thrive Capital is an investment venture capital company that operates out of New York. Thrive Capital primarily deals in internet and software investments.
Valor Equity Partners
Valor Equity Partners provides financial services to businesses in the scope of investment activities. This company is headquartered in Chicago, Illinois and was established in 2001.
What's next for NewLimit?
With this major strategic investment, NewLimit is poised for accelerated growth and the scaling of its research and development initiatives. The substantial capital infusion is expected to fuel further clinical trials, expand its scientific team, and advance its pipeline of therapies targeting age-related cellular decline. This funding round signals a critical phase for the company as it moves towards translating its groundbreaking research into tangible health solutions, potentially setting new benchmarks in the longevity and biotechnology markets.
See full NewLimit company page
